IL319242A - Dosage regimens of estrogen receptor degraders - Google Patents
Dosage regimens of estrogen receptor degradersInfo
- Publication number
- IL319242A IL319242A IL319242A IL31924225A IL319242A IL 319242 A IL319242 A IL 319242A IL 319242 A IL319242 A IL 319242A IL 31924225 A IL31924225 A IL 31924225A IL 319242 A IL319242 A IL 319242A
- Authority
- IL
- Israel
- Prior art keywords
- estrogen receptor
- dosage regimens
- receptor degraders
- degraders
- regimens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263402651P | 2022-08-31 | 2022-08-31 | |
| US202363443892P | 2023-02-07 | 2023-02-07 | |
| US202363454422P | 2023-03-24 | 2023-03-24 | |
| US202363454485P | 2023-03-24 | 2023-03-24 | |
| US202363508503P | 2023-06-15 | 2023-06-15 | |
| PCT/US2023/031574 WO2024049926A1 (en) | 2022-08-31 | 2023-08-30 | Dosage regimens of estrogen receptor degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319242A true IL319242A (en) | 2025-04-01 |
Family
ID=88192329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319242A IL319242A (en) | 2022-08-31 | 2023-08-30 | Dosage regimens of estrogen receptor degraders |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4580631A1 (en) |
| JP (1) | JP2025530742A (en) |
| KR (1) | KR20250076543A (en) |
| CN (1) | CN120112291A (en) |
| AU (1) | AU2023336057A1 (en) |
| CA (1) | CA3266061A1 (en) |
| IL (1) | IL319242A (en) |
| MX (1) | MX2025002284A (en) |
| TW (2) | TW202539669A (en) |
| WO (1) | WO2024049926A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN119258223A (en) * | 2023-07-06 | 2025-01-07 | 海创药业股份有限公司 | A combined drug for degrading estrogen receptors and its use |
| WO2026044127A1 (en) * | 2024-08-22 | 2026-02-26 | Arvinas Operations, Inc. | Administration of cyp3a inhibitors in the treatment of cancer |
| WO2026128391A1 (en) * | 2024-12-09 | 2026-06-18 | Arvinas Operations, Inc. | Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| DE602004017474D1 (en) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR |
| TWI398252B (en) | 2006-05-26 | 2013-06-11 | 諾華公司 | Pyrrolopyrimidine compound and use thereof |
| KR20090052385A (en) | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | Synthesis of 2- (pyridin-2-ylamino) -pyrido [2,3-D] pyrimidin-7-one |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| PA8852901A1 (en) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | PROTEIN CINASE INHIBITORS |
| AR083797A1 (en) | 2010-11-10 | 2013-03-20 | Novartis Ag | DIMETHYL ACID SUCCINATE 7-CYCLOPENTIL-2- (5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO) -7H-PIRROLO- [2,3-D] PIRIMIDIN-6-CARBOXILICO, PROCESS FOR PREPARE IT, INTERMEDIARIES OF SUCH SYNTHESIS AND PREPARATION PROCESS OF THE SAME |
| DK3431475T3 (en) | 2013-02-21 | 2021-05-25 | Pfizer | Solid forms of a selective CDK4 / 6 inhibitor |
| SI4197530T1 (en) | 2015-04-16 | 2026-03-31 | Novartis Ag | RIBOCYCLIB TABLET |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL303143A (en) * | 2020-12-14 | 2023-07-01 | Arvinas Operations Inc | Methods for treating cancer with tetrahydronaphthalene derivatives as estrogen receptor antagonists |
-
2023
- 2023-08-30 WO PCT/US2023/031574 patent/WO2024049926A1/en not_active Ceased
- 2023-08-30 CA CA3266061A patent/CA3266061A1/en active Pending
- 2023-08-30 CN CN202380075299.4A patent/CN120112291A/en active Pending
- 2023-08-30 IL IL319242A patent/IL319242A/en unknown
- 2023-08-30 TW TW113146678A patent/TW202539669A/en unknown
- 2023-08-30 AU AU2023336057A patent/AU2023336057A1/en active Pending
- 2023-08-30 KR KR1020257009876A patent/KR20250076543A/en active Pending
- 2023-08-30 TW TW112132871A patent/TWI866427B/en active
- 2023-08-30 JP JP2025512129A patent/JP2025530742A/en active Pending
- 2023-08-30 EP EP23776753.8A patent/EP4580631A1/en active Pending
-
2025
- 2025-02-25 MX MX2025002284A patent/MX2025002284A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3266061A1 (en) | 2024-03-07 |
| AU2023336057A1 (en) | 2025-03-27 |
| EP4580631A1 (en) | 2025-07-09 |
| TW202416991A (en) | 2024-05-01 |
| WO2024049926A1 (en) | 2024-03-07 |
| CN120112291A (en) | 2025-06-06 |
| TW202539669A (en) | 2025-10-16 |
| KR20250076543A (en) | 2025-05-29 |
| MX2025002284A (en) | 2025-06-02 |
| TWI866427B (en) | 2024-12-11 |
| JP2025530742A (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3266061A1 (en) | Dosage regimens of estrogen receptor degraders | |
| GB2595776B (en) | Therapeutic solid dosage forms | |
| IL308389A (en) | Dosage regimens for ecubectedin | |
| IL295598A (en) | Selective estrogen receptor degraders | |
| PL4370116T3 (en) | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy | |
| SG11202100145YA (en) | Selective estrogen receptor degraders | |
| ZA202201157B (en) | Selective estrogen receptor degrader | |
| IL320859A (en) | Methods of treatment of breast cancer with selective estrogen receptor degraders (serds) | |
| IL315886A (en) | Dosage regimens for anti-cd19 agents and uses thereof | |
| IL313886A (en) | Processes for the preparation of selective estrogen receptor degraders | |
| CA3295229A1 (en) | Solid oral dosage forms of estrogen receptor degraders | |
| GB202004115D0 (en) | Modified release formulations and dosage regimens | |
| CA3274497A1 (en) | Dosage forms of an estrogen receptor antagonist | |
| IL315178A (en) | Dosage regimen | |
| IL304354A (en) | Solid tablet dosage form of ridinilazole | |
| EP3932490A4 (en) | ANTIPRURITIOUS AGENT USING A PAC1 RECEPTOR ANTAGONIST | |
| EP4310079A4 (en) | ESTROGEN RECEPTOR ANTAGONIST | |
| HK40108270A (en) | Dosage regimens for ecubectedin | |
| LT3277278T (en) | Combination dosage form of a mu opioid receptor antagonist and an opioid agent | |
| CA3288633A1 (en) | Advantageous human dosage regimens for administration of inx-315 | |
| GB2621351B (en) | Metered dosage apparatus | |
| IL325443A (en) | Combination therapy for amelioration of side effects of estrogen receptor inhibitor treatment | |
| HK40087442A (en) | Preparation of an selective estrogen receptor degrader | |
| HK40105571A (en) | Dosage regimens for parp7 inhibitors | |
| GB202209299D0 (en) | Dosage regimen for antiviral therapy |